On World Cancer Day 2026, the global medical community is shifting its focus from general awareness to precision-based intervention. With breast cancer remaining the most prevalent malignancy among women globally—accounting for nearly 25% of all female cancer cases—experts argue that a “one-size-fits-all” approach to detection is no longer sufficient. Leading oncologists now emphasize that personalised breast cancer screenings are the most effective way to improve survival rates and reduce the burden of over-treatment.
In India, the situation is particularly pressing. Statistics from the National Cancer Registry Programme (NCRP) indicate that 1 in 28 Indian women will face a breast cancer diagnosis during their lifetime. More concerning is the rising incidence among younger women in urban centers, where cases are often detected at advanced stages due to inconsistent or non-specific screening protocols.
The Shift from Annual Mammograms to Risk-Based Screening
For decades, the standard medical advice was simple: every woman over a certain age should get an annual mammogram. However, the landmark WISDOM study, concluded in early 2026, has challenged this traditional model. The study proves that “risk-based” screening is not only safer but significantly more efficient than age-based rules.
By integrating factors such as breast density, family history, and genetic markers, doctors can now categorise women into specific risk groups. This allows high-risk individuals to receive more frequent, intensive monitoring, while low-risk women are spared the anxiety and “false positives” associated with unnecessary annual tests.
Understanding the 76-Variant Polygenic Risk Score
One of the most significant breakthroughs in personalised breast cancer screenings is the use of the 76-variant Polygenic Risk Score (PRS). Unlike the well-known BRCA1 and BRCA2 mutations, which represent major “errors” in a single gene, most breast cancers are the result of hundreds of tiny genetic variations called Single Nucleotide Polymorphisms (SNPs).
Think of your DNA as a massive library. A BRCA mutation is like a missing book or a torn-out chapter. In contrast, Polygenic Risk is like having hundreds of tiny typos scattered throughout different volumes. Individually, one typo might not change the story, but collectively, they significantly increase the likelihood of the disease developing. The 76-variant score specifically analyzes the most influential “typos” to predict a woman’s unique risk profile.
Why ‘Personal’ Treatment is the New Gold Standard
Dr. Gopal Sharma, Vice Chairman of Medical Oncology at Max Super Speciality Hospital, Delhi, notes that the window for Stage 1 and Stage 2 cancer offers the highest chance of a permanent cure. At these stages, the medical objective is twofold: removing the primary tumour and aggressively lowering the risk of recurrence using advanced, tailored therapies.
Every patient’s cancer biology is unique. Today, oncologists use sophisticated tools to tailor treatment based on:
- Tumour Type: Identifying specific hormone receptors (HR+, HER2+, or Triple-Negative).
- Genomic Profiling: Testing the tumour’s “signature” to see if chemotherapy is actually necessary.
- Nodal Involvement: Assessing how far the cancer has spread locally.
- Patient Age and Lifestyle: Ensuring the treatment allows the patient to maintain their daily routine.
4 Ways India is Adopting Personalised Breast Cancer Care
The landscape of oncology in India is evolving rapidly. Hospitals are moving beyond basic surgery and chemotherapy toward a more holistic, data-driven approach.
1. Decoding Tumour Biology
Breast cancer is not a single disease; it is a collection of different biological subtypes. By decoding the specific protein expressions of a tumour, doctors can avoid “over-treating” patients. This precision ensures that aggressive treatments like chemotherapy are reserved only for those who truly need them, sparing others from debilitating side effects.
2. Managing Recurrence with Precision
Even after successful surgery, the fear of the cancer returning is a major burden for survivors. In high-risk cases, the chance of recurrence can be significant. Personalised breast cancer screenings continue after treatment through advanced surveillance, genetic monitoring, and structured lifestyle coaching to manage the “what if” factor effectively.
3. Advanced Lifestyle-Integrated Therapies
Modern medicine has introduced hormone-based drugs and targeted immunotherapies designed to be “smarter” than traditional chemo. These drugs target cancer cells while leaving healthy cells largely untouched, minimising fatigue and appetite loss. This allows women to continue their careers and family lives without having to hit “pause.”
4. Prioritising Quality of Life (QoL)
In 2026, the definition of “success” in cancer care has changed. It is no longer just about a clear scan; it is about how the patient feels. Care plans now integrate mental health support, mindfulness, and peer-led recovery groups. Emotional resilience is now viewed as a clinical necessity, not just a “nice-to-have” addition.
The Future of Women’s Health in India
The findings from recent clinical trials serve as a vital reminder for the Indian demographic. When screenings are tailored to a woman’s unique genetic and biological makeup, the “ending of the story” changes. For the Indian woman, precision medicine is not just a luxury; it is a life-saving necessity that addresses unique demographic challenges and high recurrence risks.
As we observe World Cancer Day, the message is clear: Know your risk, demand a personalised plan, and move beyond basic awareness toward proactive, data-backed health decisions.
To learn more, follow Shabdsanchi’s social media pages today and stay updated.
- Facebook: shabdsanchi
- Instagram: shabdsanchiofficial
- YouTube: @shabd_sanchi
- Twitter: shabdsanchi
